Abstract
Large-scale genome-wide association studies (GWAS) have identified multiple disease-associated genetic variations across different psychiatric dis-orders raising the question of how these genetic variants relate to the corresponding pharmacological treatments. Here we investigated whether functional information from a range of open bioinformatics datasets can elucidate the relationship between GWAS-identified genetic variation and the genes targeted by current drugs for psychiatric disor-ders. We introduce a novel measure of weighted similarity between gene targets for pharmacological treatments and GWAS risk variants for psychiatric disorders according to SNP position, gene distance on the protein interaction network (PPI), brain eQTL, and gene expression pattern across the brain. Focusing on four psychiatric disorders—ADHD, bipolar disorder, schizophrenia, and major de-pressive disorder—we assess relationships between the gene targets of drug treatments and GWAS hits across these weighted similarity metrics. Our results indicate that while incorporating information derived from functional bioinformatics data, such as the PPI network and spatial gene expression, revealed links for bipolar disorder, the overall correspondence between treatment targets and GWAS-implicated genes in psychiatric disorders rarely exceeds null expectations. This relatively low degree of correspondence across modalities suggests that the genetic mechanisms driving the risk for psychiatric disorders may be distinct from the pathophysiological mechanisms used for targeting symptom manifestations through pharmacological treatments and that novel approaches for under-standing and treating psychiatric disorders may be required.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Code and links to all dataare available online at: https://github.com/AurinaBMH/GWAS_drugs